Clovis Oncology Inc

Clovis Oncology — Corporate Update (August 2021)

10 slides from Clovis Oncology's corporate update, Aug 4, 2021

  1. Slide 1: Clovis Oncology Key Strategies

    Exhibit 99.2 Clovis Oncology Key Strategies August 4, 2021

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Clovis Oncology, they are forward-looking statements reflecting the current beliefs and expectations of management. Examples of forward-looking statements contai

  3. Slide 3: Strategic Overview: Key Strategy Elements

    Strategic Overview Key Strategy Elements Label expansion to Emerge as leader Achieve long-term drive Rubraca in targeted financial stability revenue growth radionuclide therapy 3Strategic Overview Key Strategy Elements Label expansion to Emerge as leader Achieve long-term drive Rubraca in targeted f

  4. Slide 4: Drive Rubraca Revenue Growth through Label Expansion

    ® Drive Rubraca (rucaparib) Revenue Growth through Label Expansion Three topline Phase 3 data readouts over the next ~6-18 months Q1 2022 Front-line Ovarian Cancer Maintenance – ATHENA Monotherapy Q2 2022* Second-line mCRPC – TRITON3 2H 2022* Front-line I/O Combo Ovarian Cancer Maintenance – ATHENA

  5. Slide 5: FAP-2286: Our First Targeted Radionuclide Therapy (TRT)

    FAP-2286: Our First Targeted Radionuclide Therapy (TRT) FAP-2286 Lutetium-177 FAP Targeting Molecule • Peptide-targeted radionuclide therapy (PTRT) uses cancer cell-targeting peptides to deliver radiation-emitting radionuclides specifically to tumors • Fibroblast activation protein (FAP) is highly e

  6. Slide 6: FAP-2286: Key Milestones to Build Near-Term Value

    FAP-2286: Key Milestones to Build Near-Term Value First PTRT targeting FAP to enter clinical development with the Phase 1/2 LuMIERE trial open for enrollment Anticipated 2022 Milestones • First presentation of initial LuMIERE Phase 1 data • Initiation of LuMIERE Phase 2 cohorts expected in ~5 solid

  7. Slide 7: Commitment to Building a Targeted Radionuclide Therapeutic Pipeline

    Commitment to Building a Targeted Radionuclide Therapeutic Pipeline • Ongoing discovery collaboration with 3B Pharmaceuticals provides robust targeted radionuclide therapy pipeline • Potential IND for second radiotherapeutic candidate in 2H 2022 7Commitment to Building a Targeted Radionuclide Therap

  8. Slide 8: External Enthusiasm and Significant Opportunity in Emerging Targeted Radiotherapy Class

    External Enthusiasm and Significant Opportunity in Emerging Targeted Radiotherapy Class “[Targeted radiotherapy] will be the next big “We see what we treat, and we treat wave of therapeutic development.” what we see” Ø Dr. Charles Kunos, University of Kentucky, Ø Prof. Dr. Richard P. Baum, Theranost

  9. Slide 9: Commitment to Achieve Long-term Financial Stability

    Commitment to Achieve Long-term Financial Stability Drive Rubraca revenue growth in US and Europe Three Rubraca Phase 3 trial read-outs in next 6-18 months Increase Rubraca revenues with label expansion Reduced R&D spend on Rubraca, new R&D spend dedicated to targeted radionuclide therapy program Lo

  10. Slide 10: Strategic Overview: Key Strategy Elements

    Strategic Overview Key Strategy Elements Label expansion to Emerge as leader Achieve long-term drive Rubraca in targeted financial stability revenue growth radionuclide therapy 10Strategic Overview Key Strategy Elements Label expansion to Emerge as leader Achieve long-term drive Rubraca in targeted

Clovis Oncology — Corporate Update (August 2021) on 6ix